BioPorto Management

Management criteria checks 2/4

BioPorto's CEO is Peter Eriksen, appointed in Jan 2024, has a tenure of less than a year. directly owns 0.18% of the company’s shares, worth DKK1.70M. The average tenure of the management team and the board of directors is 0.5 years and 10.5 years respectively.

Key information

Peter Eriksen

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	0.2%
Management average tenure	less than a year
Board average tenure	10.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Peter Eriksen's remuneration changed compared to BioPorto's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-DKK 54m
Dec 31 2023	n/a	n/a	-DKK 56m
Sep 30 2023	n/a	n/a	-DKK 70m
Jun 30 2023	n/a	n/a	-DKK 78m
Mar 31 2023	n/a	n/a	-DKK 75m
Dec 31 2022	DKK 292k	n/a	-DKK 76m
Sep 30 2022	n/a	n/a	-DKK 68m
Jun 30 2022	n/a	n/a	-DKK 62m
Mar 31 2022	n/a	n/a	-DKK 59m
Dec 31 2021	DKK 3m	n/a	-DKK 57m
Sep 30 2021	n/a	n/a	-DKK 54m
Jun 30 2021	n/a	n/a	-DKK 60m
Mar 31 2021	n/a	n/a	-DKK 62m
Dec 31 2020	DKK 7m	DKK 3m	-DKK 62m
Sep 30 2020	n/a	n/a	-DKK 64m
Jun 30 2020	n/a	n/a	-DKK 68m
Mar 31 2020	n/a	n/a	-DKK 69m
Dec 31 2019	DKK 6m	DKK 3m	-DKK 70m
Sep 30 2019	n/a	n/a	-DKK 61m
Jun 30 2019	n/a	n/a	-DKK 51m
Mar 31 2019	n/a	n/a	-DKK 43m
Dec 31 2018	DKK 4m	DKK 3m	-DKK 38m
Sep 30 2018	n/a	n/a	-DKK 38m
Jun 30 2018	n/a	n/a	-DKK 36m
Mar 31 2018	n/a	n/a	-DKK 35m
Dec 31 2017	DKK 5m	DKK 3m	-DKK 32m

Compensation vs Market: Insufficient data to establish whether Peter's total compensation is reasonable compared to companies of similar size in the UK market.

Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.

CEO

Peter Eriksen (64 yo)

less than a year

Tenure

DKK 292,000

Compensation

Mr. Peter Mørch Eriksen, BBA, serves as Chief Executive Officer at BioPorto A/S. He served as a Director of BioPorto A/S since November 15, 2021 until April 30, 2024 and served as its Interim CEO from Janu...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Peter Eriksen	Chief Executive Officer	less than a year	DKK 292.00k	0.18% DKK 1.7m
Lars Uttenthal	Chief Scientific Officer	no data	no data	no data
Gry Larsen	Executive VP & Chief Legal Officer	less than a year	no data	no data
Jennifer Zonderman	SVP of Global Marketing & US Commercialization	5.2yrs	no data	no data
Nis Kruse	Executive VP of Strategic Partnerships and GM of EMEA & APAC	1.6yrs	no data	no data
Jeffrey Haas	President & CEO of BioPorto Inc.	less than a year	no data	no data

0.5yrs

Average Tenure

Experienced Management: 0JJM's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Donnie Hardison	Independent Vice Chairman of the Board	3.3yrs	DKK 795.00k	0.0046% DKK 44.1k
John McDonough	Independent Chairman of the Board	3.3yrs	DKK 1.08m	0.095% DKK 899.1k
Claudio Ronco	Member of Scientific Advisory Board	10.5yrs	no data	no data
Mats Thoren	Director	no data	no data	no data
Jean-Louis Vincent	Chairman of the Scientific Advisory Board	10.5yrs	no data	no data
Henrik Juuel	Director	no data	no data	no data
Ninfa Saunders	Independent Director	1.3yrs	DKK 458.00k	no data
Michael Singer	Independent Director	4.9yrs	DKK 674.00k	no data
Andrew Lewington	Vice Chairman of Scientific Advisory Board	10.5yrs	no data	no data
Laurent Jacob	Member of Scientific Advisory Board	10.5yrs	no data	no data
Michael Haase	Member of Scientific Advisory Board	10.5yrs	no data	no data
Hilde Geus	Member of Scientific Advisory Board	10.5yrs	no data	no data

10.5yrs

Average Tenure

61.5yo

Average Age

Experienced Board: 0JJM's board of directors are seasoned and experienced ( 10.5 years average tenure).

BioPorto Management

Management criteria checks 2/4

Key information

Recent management updates

BioPorto A/S Appoints Niels Høy Nielsen as Member of the Executive Management Team, Effective August 1, 2024

Bioporto A/S Appoints Gry Louise Husby Larsen as Chief Legal Officer and Member of the Executive Management Team, Effective as of April 15, 2024

Bioporto A/S Announces Tonni Bülow-Nielsennot to Stand for Election

BioPorto A/S Announces CEO Changes

BioPorto A/S, Annual General Meeting, Apr 30, 2024

BioPorto A/S Announces Resignation of Jan Leth Christensen as Board Member

Recent updates

Bioporto A/S Affirms Earnings Guidance for 2024

BioPorto A/S Appoints Niels Høy Nielsen as Member of the Executive Management Team, Effective August 1, 2024

Bioporto A/S Provides Revenue Guidance for 2024

Bioporto A/S Appoints Gry Louise Husby Larsen as Chief Legal Officer and Member of the Executive Management Team, Effective as of April 15, 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings released: kr.0.16 loss per share (vs kr.0.24 loss in FY 2022)

Bioporto A/S Announces Tonni Bülow-Nielsennot to Stand for Election

New minor risk - Market cap size

BioPorto A/S Announces CEO Changes

BioPorto A/S to Report First Half, 2024 Results on Aug 01, 2024

BioPorto A/S, Annual General Meeting, Apr 30, 2024

BioPorto A/S Receives FDA 510(k) Clearance for NGAL Test in the United States

BioPorto A/S Announces Resignation of Jan Leth Christensen as Board Member

Third quarter 2023 earnings released: kr.0.03 loss per share (vs kr.0.05 loss in 3Q 2022)

Bioporto A/S Provides Revenue Guidance for the Fiscal Year 2023

No longer forecast to breakeven

Bioporto A/S Announces Resignation of Neil Goldman as CFO

BioPorto A/S announced that it has received $0.11 million in funding

BioPorto A/S Maintains Earnings Guidance for the Year 2023

BioPorto A/S Maintains Financial Guidance for 2023

Less than half of directors are independent

Full year 2022 earnings released: kr.0.24 loss per share (vs kr.0.21 loss in FY 2021)

Less than half of directors are independent

Less than half of directors are independent

BioPorto A/S to Report Q1, 2023 Results on May 10, 2023

Less than half of directors are independent

BioPorto A/S Appoints Nis Kruse as EVP of Strategic Partnerships and Gm of EMEA & Apac

Less than half of directors are independent

BioPorto A/S Submits Application for Marketing Authorization of NGAL Test to the US Food and Drug Administration

BioPorto A/S Revises Earnings Guidance for the Year 2022

Less than half of directors are independent

Less than half of directors are independent

BioPorto A/S Revises Earnings Guidance for the Year 2022

BioPorto A/S Revises Earnings Guidance for the Year 2022

BioPorto A/S Achieves Targeted Enrollment in Clinical Study Supporting FDA De Novo Submission for The NGAL Test in the U.S

BioPorto A/S Appoints Dr. Prasad Devarajan as New Senior Medical Director

BioPorto A/S Maintains its Earnings Guidance for the Year 2022

BioPorto A/S Provides Earnings Guidance for the Full Year 2022

Less than half of directors are independent

Less than half of directors are independent

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age